Study of Rapastinel as Monotherapy in Patients With MDD
Status:
Terminated
Trial end date:
2019-07-08
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900
milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive
disorder (MDD).